CA3051828A1 - Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor - Google Patents
Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor Download PDFInfo
- Publication number
- CA3051828A1 CA3051828A1 CA3051828A CA3051828A CA3051828A1 CA 3051828 A1 CA3051828 A1 CA 3051828A1 CA 3051828 A CA3051828 A CA 3051828A CA 3051828 A CA3051828 A CA 3051828A CA 3051828 A1 CA3051828 A1 CA 3051828A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- administered
- amount
- response
- study
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662287858P | 2016-01-27 | 2016-01-27 | |
| US62/287,858 | 2016-01-27 | ||
| PCT/US2017/015237 WO2017132445A1 (en) | 2016-01-27 | 2017-01-27 | Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3051828A1 true CA3051828A1 (en) | 2017-08-03 |
Family
ID=59398691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3051828A Pending CA3051828A1 (en) | 2016-01-27 | 2017-01-27 | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190111053A1 (https=) |
| EP (1) | EP3407887B1 (https=) |
| JP (1) | JP6964593B2 (https=) |
| CN (1) | CN109475543A (https=) |
| CA (1) | CA3051828A1 (https=) |
| WO (1) | WO2017132445A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160004299A (ko) | 2013-04-09 | 2016-01-12 | 릭스트 바이오테크놀로지, 인코포레이티드 | 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형 |
| ES2985668T3 (es) | 2015-05-15 | 2024-11-06 | Lixte Biotechnology Inc | Profármacos de oxabicicloheptano para uso en el tratamiento del cáncer |
| WO2018027144A1 (en) * | 2016-08-04 | 2018-02-08 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Companion diagnostic for combination lenalidomide and erythropoietin treatment |
| EP4324477A3 (en) | 2016-12-08 | 2024-05-22 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for modulation of immune response |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080267947A1 (en) | 2006-09-07 | 2008-10-30 | Cirrito Thomas P | Cancer therapy with cantharidin and cantharidin analogs |
| BRPI0806365B8 (pt) | 2007-02-06 | 2021-05-25 | Lixte Biotechnology Holdings Inc | composto, uso do composto, composição farmacêutica e uso da composição farmacêutica |
| KR20160004299A (ko) * | 2013-04-09 | 2016-01-12 | 릭스트 바이오테크놀로지, 인코포레이티드 | 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형 |
| EP3171870B1 (en) * | 2014-07-24 | 2021-10-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes |
| WO2016040877A1 (en) * | 2014-09-12 | 2016-03-17 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
-
2017
- 2017-01-27 WO PCT/US2017/015237 patent/WO2017132445A1/en not_active Ceased
- 2017-01-27 CA CA3051828A patent/CA3051828A1/en active Pending
- 2017-01-27 CN CN201780019895.5A patent/CN109475543A/zh active Pending
- 2017-01-27 JP JP2018540013A patent/JP6964593B2/ja not_active Expired - Fee Related
- 2017-01-27 US US16/072,963 patent/US20190111053A1/en not_active Abandoned
- 2017-01-27 EP EP17744934.5A patent/EP3407887B1/en not_active Not-in-force
-
2022
- 2022-03-04 US US17/687,231 patent/US20220323433A2/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109475543A (zh) | 2019-03-15 |
| US20220184066A1 (en) | 2022-06-16 |
| JP2019507134A (ja) | 2019-03-14 |
| EP3407887A4 (en) | 2019-09-25 |
| WO2017132445A1 (en) | 2017-08-03 |
| US20190111053A1 (en) | 2019-04-18 |
| EP3407887B1 (en) | 2021-09-01 |
| JP6964593B2 (ja) | 2021-11-10 |
| US20220323433A2 (en) | 2022-10-13 |
| EP3407887A1 (en) | 2018-12-05 |
| WO2017132445A8 (en) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220323433A2 (en) | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
| CN105705148B (zh) | 使用普那布林和紫杉烷的组合的癌症疗法 | |
| KR20230148208A (ko) | 골수섬유증과 같은 혈액 악성종양을 치료하기 위한 bet 억제제 단독 또는 페드라티닙 또는 룩솔리티닙과의 조합물의 용도 | |
| AU2012321106B2 (en) | Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent | |
| US20100098702A1 (en) | Method of treating androgen independent prostate cancer | |
| JP6833816B2 (ja) | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） | |
| KR102613106B1 (ko) | Ｂ―세포 악성종양의 치료를 위한 세르둘라티닙 | |
| AU2016285597A1 (en) | Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of cancer | |
| CN114246864B (zh) | Csf1r激酶抑制剂及其用途 | |
| WO2016168451A1 (en) | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment | |
| US10576050B2 (en) | Methods and compositions for treatment of cancer | |
| WO2022090443A1 (en) | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor | |
| KR20150090091A (ko) | 볼라세르티브와의 병용 요법 | |
| EP4095137A1 (en) | Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma | |
| CN115038447A (zh) | 用于治疗癌症的组合疗法 | |
| HK40000014B (en) | Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
| CN1901906B (zh) | 治疗套细胞淋巴瘤的cci-779 | |
| CN116492342B (zh) | 氯喹或羟氯喹在制备治疗尼洛替尼肾脏毒副作用药物中的应用 | |
| HK40085748A (en) | Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma | |
| EP4684788A1 (en) | Pharmaceutical composition and use thereof | |
| EP4729061A1 (en) | Use of akt inhibitor in preparation of drug for preventing or treating breast cancer | |
| WO2023220396A1 (en) | Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor | |
| Arrillaga-Romany et al. | ACTR-33. TUMOR TISSUE PENETRATION AND PHARMACODYNAMICS OF ONC201 IN ADULT RECURRENT GLIOBLASTOMA PATIENTS | |
| HK40092504A (zh) | 治疗癌症的bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物 | |
| CN119367370A (zh) | 用于治疗肺癌的联合药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220114 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20240729 |
|
| N11 | Application terminated |
Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE Effective date: 20250729 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260318 |